ArticleFrontiers in pharmacology2015
Pharmacological profiling of zebrafish behavior using chemical and genetic classification of sleep-wake modifiers.
Article in Frontiers in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Characteristics of the sleep structure in the cleaner wrasse Labroides dimidiatus.Zoological letters · 2026Article
- Delivering Traumatic Brain Injury to Larval Zebrafish.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- Investigating the effects of chronic low-dose radiation exposure in the liver of a hypothermic zebrafish model.Scientific reports · 2023Article
- Modulation of sleep behavior in zebrafish larvae by pharmacological targeting of the orexin receptor.Frontiers in pharmacology · 2022Article
- Induced Torpor as a Countermeasure for Low Dose Radiation Exposure in a Zebrafish Model.Cells · 2021Article
- An Integrated In Silico and In Vivo Approach to Identify Protective Effects of Palonosetron in Cisplatin-Induced Nephrotoxicity.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Use of Zebrafish in Drug Discovery Toxicology.Chemical research in toxicology · 2020Review
- C3orf70 Is Involved in Neural and Neurobehavioral Development.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Genetic Signatures of Drug Response Variability inGenetics · 2019Article
- Attacking sleep from a new angle: contributions from zebrafish.Current opinion in neurobiology · 2017Review
- Article
- The Hypocretin/Orexin Neuronal Networks in Zebrafish.Current topics in behavioral neurosciences · 2017Review
- Unraveling the Evolutionary Determinants of Sleep.Current biology : CB · 2016Review
- Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases.Oxidative medicine and cellular longevity · 2016Review
- E2F4 Promotes Neuronal Regeneration and Functional Recovery after Spinal Cord Injury in Zebrafish.Frontiers in pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep-wake states are impaired in various neurological disorders. Impairment of sleep-wake states can be an early condition that exacerbates these disorders. Therefore, treating sleep-wake dysfunction may prevent or slow the development of these diseases. Although many gene products are likely to be involved in the sleep-wake disturbance, hypnotics and psychostimulants clinically used are limited in terms of their mode of action and are not without side effects. Therefore, there is a growing demand for developing new hypnotics and psychostimulants with high efficacy and few side effects. Toward this end, animal models are indispensable for use in genetic and chemical screens to identify sleep-wake modifiers. As a proof-of-concept study, we performed behavioral profiling of zebrafish treated with chemical and genetic sleep-wake modifiers. We were able to demonstrate that behavioral profiling of zebrafish treated with hypnotics or psychostimulants from 9 to 10 days post-fertilization was sufficient to identify drugs with specific modes of action. We were also able to identify behavioral endpoints distinguishing GABA-A modulators and hypocretin (hcrt) receptor antagonists and between sympathomimetic and non-sympathomimetic psychostimulants. This behavioral profiling can serve to identify genes related to sleep-wake disturbance associated with various neuropsychiatric diseases and novel therapeutic compounds for insomnia and excessive daytime sleep with fewer adverse side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.